Neurocrine Biosciences Beheer
Beheer criteriumcontroles 4/4
De CEO Neurocrine Biosciences is Kyle Gano, benoemd in Jan2011, heeft een ambtstermijn van 13.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.99M, bestaande uit 10.1% salaris en 89.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 17.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.9 jaar en 9.1 jaar.
Belangrijke informatie
Kyle Gano
Algemeen directeur
US$6.0m
Totale compensatie
Percentage CEO-salaris | 10.1% |
Dienstverband CEO | 13.8yrs |
Eigendom CEO | 0.1% |
Management gemiddelde ambtstermijn | 6.9yrs |
Gemiddelde ambtstermijn bestuur | 9.1yrs |
Recente managementupdates
Recent updates
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
Oct 10The Play On Neurocrine Biosciences
Oct 02Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Aug 28Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
May 08Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Apr 27Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$386m |
Jun 30 2024 | n/a | n/a | US$339m |
Mar 31 2024 | n/a | n/a | US$370m |
Dec 31 2023 | US$6m | US$603k | US$250m |
Sep 30 2023 | n/a | n/a | US$191m |
Jun 30 2023 | n/a | n/a | US$176m |
Mar 31 2023 | n/a | n/a | US$64m |
Dec 31 2022 | US$5m | US$551k | US$155m |
Sep 30 2022 | n/a | n/a | US$58m |
Jun 30 2022 | n/a | n/a | US$12m |
Mar 31 2022 | n/a | n/a | US$71m |
Dec 31 2021 | US$6m | US$517k | US$90m |
Sep 30 2021 | n/a | n/a | US$445m |
Jun 30 2021 | n/a | n/a | US$365m |
Mar 31 2021 | n/a | n/a | US$402m |
Dec 31 2020 | US$7m | US$488k | US$407m |
Sep 30 2020 | n/a | n/a | US$93m |
Jun 30 2020 | n/a | n/a | US$205m |
Mar 31 2020 | n/a | n/a | US$177m |
Dec 31 2019 | US$5m | US$443k | US$37m |
Sep 30 2019 | n/a | n/a | US$21m |
Jun 30 2019 | n/a | n/a | US$18m |
Mar 31 2019 | n/a | n/a | -US$39m |
Dec 31 2018 | US$5m | US$403k | US$21m |
Sep 30 2018 | n/a | n/a | US$10m |
Jun 30 2018 | n/a | n/a | -US$52m |
Mar 31 2018 | n/a | n/a | -US$106m |
Dec 31 2017 | US$2m | US$375k | -US$143m |
Compensatie versus markt: De totale vergoeding ($USD 5.99M ) Kyle } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.66M ).
Compensatie versus inkomsten: De vergoeding van Kyle is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Kyle Gano (51 yo)
13.8yrs
Tenure
US$5,990,215
Compensatie
Mr. Kyle W. Gano, Ph D., is CEO and Director at Neurocrine Biosciences, Inc since October 11, 2024. He was Chief Business Development and Strategy Officer at Neurocrine Biosciences, Inc. since 2020 until O...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | 13.8yrs | US$5.99m | 0.13% $ 17.0m | |
Chief Financial Officer | 7yrs | US$6.06m | 0.031% $ 4.0m | |
Chief Scientific Officer | 3yrs | US$7.22m | 0.013% $ 1.7m | |
Chief Medical Officer | 6.8yrs | US$5.87m | 0.031% $ 3.9m | |
Head of Investor Relations | no data | geen gegevens | geen gegevens | |
Chief Legal Officer & Corporate Secretary | 10.1yrs | US$4.72m | 0.039% $ 5.0m | |
Chief Human Resources Officer | 7.2yrs | geen gegevens | 0.018% $ 2.3m | |
Chief Commercial Officer | 9.5yrs | US$5.81m | 0.040% $ 5.1m | |
Chief Corporate Affairs Officer | 5.2yrs | geen gegevens | 0.00037% $ 47.1k | |
Chief Regulatory Officer | 2.1yrs | geen gegevens | 0.0025% $ 315.5k | |
Exclusive Consultant | 6.8yrs | US$3.10m | geen gegevens |
6.9yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NBIX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.9 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | less than a year | US$5.99m | 0.13% $ 17.0m | |
Independent Director | 1.3yrs | US$813.45k | 0% $ 0 | |
Independent Director | 26.6yrs | US$492.04k | 0.031% $ 4.0m | |
Independent Director | 25.6yrs | US$479.54k | 0.024% $ 3.1m | |
Independent Chairman of the Board | 14.8yrs | US$495.04k | 0.037% $ 4.7m | |
Independent Director | 31.8yrs | US$460.11k | 0.12% $ 15.0m | |
Independent Director | 9.1yrs | US$479.54k | 0.0042% $ 527.9k | |
Director | 16.8yrs | US$15.75m | 0.51% $ 64.7m | |
Independent Director | 4.8yrs | US$497.11k | 0.00098% $ 124.7k | |
Independent Director | 5.2yrs | US$475.11k | 0.00098% $ 124.7k | |
Independent Director | 3.6yrs | US$467.61k | 0.0021% $ 263.3k |
9.1yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NBIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.1 jaar).